All Stories

  1. Pharmacokinetics, Pharmacodynamics, Efficacy and Drug Resistance Selection of Injectable Long‐Acting Lenacapavir Pre‐Exposure Prophylaxis ( PrEP ) Against HIV
  2. SIMPLICITY is an agent-based, multi-scale mathematical model to study SARS-CoV-2 intra- and between-host evolution
  3. Behavior change and infection induced immunity led to the decline of the 2022 Mpox outbreak in Berlin
  4. Pharmacological markers of HIV prevention for oral pre-exposure prophylaxis in MSM
  5. Pharmacokinetics, pharmacodynamics, efficacy and drug resistance selection of injectable long-acting lenacapavir pre-exposure prophylaxis (PrEP) against HIV
  6. Atypical Influenza A(H3N2) Activity Patterns in Germany, 2021–2023, and Characterization of Newly Emerged Virus Clades
  7. Non-cell autonomous control of presynaptic remodeling by the hypothalamic autophagy/NPY axis
  8. Efficient and accurate simulation of infectious diseases on adaptive networks
  9. Modelling the impact of initiation delay, duration and prior PrEP on the efficacy of post‐exposure prophylaxis containing a tenofovir/emtricitabine backbone
  10. Sequential and independent probabilistic events regulate differential axon targeting during development in Drosophila melanogaster
  11. Demultiplexing and barcode-specific adaptive sampling for nanopore direct RNA sequencing
  12. Native epitranscriptome sequencing reveals Hepatitis B virus RNA stability protected by heavy m6A modification
  13. Efficient and accurate simulation of infectious diseases on adaptive networks
  14. Demultiplexing and barcode-specific adaptive sampling for nanopore direct RNA sequencing
  15. Modeling of HIV‐1 prophylactic efficacy and toxicity with islatravir shows non‐superiority for oral dosing, but promise as a subcutaneous implant
  16. Modelling the impact of initiation delay, duration and prior PrEP usage on the prophylactic efficacy of FTC/TDF-containing post-exposure prophylaxis
  17. Multi-Input data ASsembly for joint Analysis (MIASA): A framework for the joint analysis of disjoint sets of variables
  18. Modeling of HIV-1 prophylactic efficacy and toxicity with islatravir shows non-superiority for oral dosing, but promise as a subdermal implant
  19. Axonal self-sorting without target guidance in Drosophila visual map formation
  20. Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women
  21. SARS-CoV-2 Evolution on a Dynamic Immune Landscape
  22. T-Cell-Dominated Immune Response Resolves Protracted SARS-CoV-2 Infection in the Absence of Neutralizing Antibodies in an Immunocompromised Individual
  23. Sequencing accuracy and systematic errors in nanopore direct RNA sequencing
  24. Leveraging Secondary Data for Global Health Digitalization
  25. Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021
  26. Short- and long-range interactions in the HIV-1 5′ UTR regulate genome dimerization and packaging
  27. Investigation of a Limited but Explosive COVID-19 Outbreak in a German Secondary School
  28. S̲tochastic S̲imulation A̲lgorithm For Effective Spreading Dynamics On T̲ime-Evolving A̲daptive N̲etworX̲ (SSATAN-X)
  29. Numerical approaches for the rapid analysis of prophylactic efficacy against HIV with arbitrary drug-dosing schemes
  30. Brain connectivity inversely scales with developmental temperature in Drosophila
  31. Stochastic Simulation Algorithm for effective spreading dynamics on Time-evolving Adaptive NetworX (SSATAN-X)
  32. Rapid incidence estimation from SARS-CoV-2 genomes reveals decreased case detection in Europe during summer 2020
  33. Inferring gene regulatory networks from single-cell RNA-seq temporal snapshot data requires higher-order moments
  34. Rise and Fall of SARS-CoV-2 Lineage A.27 in Germany
  35. Numerical approaches for the rapid analysis of prophylactic efficacy against HIV with arbitrary drug-dosing schemes
  36. Mathematical Modelling of the Molecular Mechanisms of Interaction of Tenofovir with Emtricitabine against HIV
  37. Trends in respiratory virus circulation following COVID-19-targeted nonpharmaceutical interventions in Germany, January - September 2020: Analysis of national surveillance data
  38. Rapid incidence estimation from SARS-CoV-2 genomes reveals decreased case detection in Europe during summer 2020
  39. Rapid incidence estimation from SARS-CoV-2 genomes reveals decreased case detection in Europe during summer 2020
  40. Variable brain wiring through scalable and relative synapse formation in Drosophila
  41. ITN—VIROINF: Understanding (Harmful) Virus-Host Interactions by Linking Virology and Bioinformatics
  42. On the Sufficient Condition for Solving the Gap-Filling Problem Using Deep Convolutional Neural Networks
  43. COVIDStrategyCalculator: A standalone software to assess testing- and quarantine strategies for incoming travelers, contact person management and de-isolation
  44. Computational strategies to combat COVID-19: useful tools to accelerate SARS-CoV-2 and coronavirus research
  45. Editorial: Pharmacokinetics and Pharmacodynamics of Pre-Exposure Prophylaxis Against HIV
  46. Local c-di-GMP Signaling in the Control of Synthesis of the E. coli Biofilm Exopolysaccharide pEtN-Cellulose
  47. Autophagy-dependent filopodial kinetics restrict synaptic partner choice during Drosophila brain wiring
  48. Serial Synapse Formation through Filopodial Competition for Synaptic Seeding Factors
  49. SLCV–a supervised learning—computer vision combined strategy for automated muscle fibre detection in cross-sectional images
  50. Discerning the spatio-temporal disease patterns of surgically induced OA mouse models
  51. Reconstruction of the Genetic History and the Current Spread of HIV-1 Subtype A in Germany
  52. The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis
  53. Analysis of long non-coding RNA and mRNA expression in bovine macrophages brings up novel aspects of Mycobacterium avium subspecies paratuberculosis infections
  54. Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis
  55. Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes
  56. In cell mutational interference mapping experiment (in cell MIME) identifies the 5′ polyadenylation signal as a dual regulator of HIV-1 genomic RNA production and packaging
  57. Statistical Analysis of the First Passage Path Ensemble of Jump Processes
  58. Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors
  59. In silico cytotoxicity assessment on cultured rat intestinal cells deduced from cellular impedance measurements
  60. Inferring HIV-1 Transmission Dynamics in Germany From Recently Transmitted Viruses
  61. Top-down and bottom-up models for nucleoside reverse transcriptase inhibitors against HIV-1
  62. MIMEAnTo: profiling functional RNA in mutational interference mapping experiments
  63. Systems-pharmacology modelling pipeline for PrEP against HIV-1
  64. Coupling cellular phenotype and mechanics to understand extracellular matrix formation and homeostasis in osteoarthritis * *financial support through BMBF project OVERLOAD-PrevOp, grant number 01EC1408H is acknowledged.
  65. Mutational interference mapping experiment (MIME) for studying RNA structure and function
  66. Logical-continuous modelling of post-translationally regulated bistability of curli fiber expression in Escherichia coli
  67. Optimal Treatment Strategies in the Context of ‘Treatment for Prevention’ against HIV-1 in Resource-Poor Settings
  68. Characterization of natural polymorphic sites of the HIV-1 integrase before the introduction of HIV-1 integrase inhibitors in Germany
  69. Assessment of Ambiguous Base Calls in HIV-1 pol Population Sequences as a Biomarker for Identification of Recent Infections in HIV-1 Incidence Studies
  70. Awareness and Utilization of Reporting Pathways for Adverse Events Following Immunization: Online Survey Among Pediatricians in Russia and Germany
  71. 'Time-to-amphotericin B' in cryptococcal meningitis in a European low-prevalence setting: analysis of diagnostic delays
  72. Quantitative Influenza Follow-Up Testing (QIFT)—A Novel Biomarker for the Monitoring of Disease Activity at the Point-of-Care
  73. Markov control processes with rare state observation: theory and application to treatment scheduling in HIV–1
  74. Towards a Personalised Approach to Managing Influenza Infections in Infants and Children – Food for Thought and a Note on Oseltamivir
  75. In Vitro HIV-1 Evolution in Response to Triple Reverse Transcriptase Inhibitors & In Silico Phenotypic Analysis
  76. Antiviral Resistance and Correlates of Virologic Failure in the first Cohort of HIV-Infected Children Gaining Access to Structured Antiretroviral Therapy in Lima, Peru: A Cross-Sectional Analysis
  77. Virus Load Kinetics and Resistance Development During Oseltamivir Treatment in Infants and Children Infected With Influenza A(H1N1) 2009 and Influenza B Viruses
  78. Pharmacokinetics and Pharmacodynamics of the Reverse Transcriptase Inhibitor Tenofovir and Prophylactic Efficacy against HIV-1 Infection
  79. HIV-1 Polymerase Inhibition by Nucleoside Analogs: Cellular- and Kinetic Parameters of Efficacy, Susceptibility and Resistance Selection
  80. Quantifying the Impact of Nevirapine-Based Prophylaxis Strategies To Prevent Mother-to-Child Transmission of HIV-1: a Combined Pharmacokinetic, Pharmacodynamic, and Viral Dynamic Analysis To Predict Clinical Outcomes
  81. HIV Quasispecies Dynamics during Pro-Active Treatment Switching: Impact on Multi-Drug Resistance and Resistance Archiving in Latent Reservoirs
  82. Drug-Class Specific Impact of Antivirals on the Reproductive Capacity of HIV
  83. Pharmacokinetic–pharmacodynamic relationship of NRTIs and its connection to viral escape: An example based on zidovudine
  84. Physiologically based pharmacokinetic modelling: a sub-compartmentalized model of tissue distribution
  85. Software Supported Modelling in Pharmacokinetics
  86. Update on Antiviral DNA Vaccine Research (2000–2003)